| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 23/04/2024 | 13:25 | IH Market News | Apple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More News | NYSE:NVS | Novartis AG |
| 15/04/2024 | 20:00 | PR Newswire (US) | New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN) | NYSE:NVS | Novartis AG |
| 11/04/2024 | 13:00 | GlobeNewswire Inc. | Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer | NYSE:NVS | Novartis AG |
| 10/04/2024 | 13:13 | IH Market News | Delta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More News | NYSE:NVS | Novartis AG |
| 06/04/2024 | 22:16 | PR Newswire (US) | New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting | NYSE:NVS | Novartis AG |
| 15/02/2024 | 22:15 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NYSE:NVS | Novartis AG |
| 06/02/2024 | 22:52 | Edgar (US Regulatory) | Form SC TO-C - Written communication relating to an issuer or third party | NYSE:NVS | Novartis AG |
| 06/02/2024 | 12:14 | IH Market News | Boeing Faces Strike Threat, Palantir Up 18% After Recording its First Profitable Year, and More | NYSE:NVS | Novartis AG |
| 02/02/2024 | 20:18 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NYSE:NVS | Novartis AG |
| 31/01/2024 | 13:44 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NYSE:NVS | Novartis AG |
| 31/01/2024 | 13:42 | Edgar (US Regulatory) | Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)). | NYSE:NVS | Novartis AG |
| 31/01/2024 | 13:38 | Edgar (US Regulatory) | Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | NYSE:NVS | Novartis AG |
| 31/01/2024 | 12:28 | IH Market News | Walmart’s Stock Split, Elon Musk’s Billion-Dollar Package Revoked, and More | NYSE:NVS | Novartis AG |
| 22/01/2024 | 07:59 | Dow Jones News | Sandoz to Acquire Cimerli Business from Coherus for $170 Million | NYSE:NVS | Novartis AG |
| 12/01/2024 | 12:10 | IH Market News | Wall Street Highlights: DocuSign Acquisition Battle, Tesla Berlin Production Halt, and More | NYSE:NVS | Novartis AG |
| 11/01/2024 | 19:02 | Dow Jones News | Cytokinetics Shares Slide as Novartis Reportedly Shies Away From Deal | NYSE:NVS | Novartis AG |
| 08/01/2024 | 19:43 | Dow Jones News | Cytokinetics Shares Jump 16% After WSJ Report of Novartis Deal | NYSE:NVS | Novartis AG |
| 08/01/2024 | 16:41 | Dow Jones News | Novartis on Track for Record High Close -- Data Talk | NYSE:NVS | Novartis AG |
| 08/01/2024 | 08:01 | Dow Jones News | Novartis's Scemblix Drug Meets Main Goals in Late-Stage Leukemia Trial | NYSE:NVS | Novartis AG |
| 05/01/2024 | 16:15 | Dow Jones News | Novartis to Make Pluvicto Radioligand Therapy at Indianapolis Plant | NYSE:NVS | Novartis AG |
| 02/01/2024 | 13:46 | Dow Jones News | Voyager Therapeutics Shares Leap Premarket on Novartis Collaboration | NYSE:NVS | Novartis AG |
| 11/12/2023 | 08:02 | Dow Jones News | Novartis Drug Meets Primary Goal in Late-Stage Study for Kidney Disease | NYSE:NVS | Novartis AG |
| 11/12/2023 | 01:39 | PR Newswire (US) | Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH) | NYSE:NVS | Novartis AG |
| 06/12/2023 | 11:14 | Dow Jones News | Merck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage Trials | NYSE:NVS | Novartis AG |
| 06/12/2023 | 06:18 | PR Newswire (US) | Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH | NYSE:NVS | Novartis AG |
| 05/12/2023 | 12:25 | IH Market News | Moody’s Reassesses China, GitLab Exceeds Estimates, Twilio Plans Major Layoffs, and More | NYSE:NVS | Novartis AG |
| 29/11/2023 | 12:18 | IH Market News | Amazon Unveils Innovative Services, Okta Discloses Data Breach, Textron Plans 2% Global Workforce Reduction, and More | NYSE:NVS | Novartis AG |
| 28/11/2023 | 21:08 | Dow Jones News | FDA Looking Into All Approved CAR T Therapies on Risk of Cancer in White Blood Cells | NYSE:NVS | Novartis AG |
| 28/11/2023 | 08:12 | Dow Jones News | Novartis Raises Mid-Term Sales Growth Targets | NYSE:NVS | Novartis AG |
| 13/11/2023 | 15:16 | Dow Jones News | Legend Biotech Subsidiary in License Agreement With Novartis | NYSE:NVS | Novartis AG |